Enrollment Closed studies:
M-STAR A randomized, Double-Blind, Placebo Controlled to Evaluate Efficacy and Safety of BHV3241 in Patients with MSA
- The main objective of this study is to evaluate whether the study drug can slow down disease progression in individuals with multiple system atrophy.
- People with multiple system atrophy will use an oral medication (study drug or placebo) twice daily for about 11 months. The study will involve up to seven visits. Neurological examination and neuropsychological testing will be performed at each visit. A study partner/caregiver is required.
For further information about this and other studies, please contact Aishwarya Niraula by email email@example.com or phone 858-246-3190.